These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4153252)

  • 1. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 2. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 3. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P; Rondot P; Taberlet A; Baumann N
    Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
    [No Abstract]   [Full Text] [Related]  

  • 4. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 5. How to achieve maximum benefit for the patient with Parkinson's disease.
    Greer M
    Geriatrics; 1976 Apr; 31(4):89-96. PubMed ID: 4356
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacology of parkinsonism (a review).
    Klawans HL
    Dis Nerv Syst; 1968 Dec; 29(12):805-16. PubMed ID: 4388368
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disease improvement after the addition of levodopa-carbidopa to anticholinergic treatment. An open controlled study.
    Agnoli A; Ruggieri S; Denaro A; Lelli A
    Acta Neurol (Napoli); 1978 Oct; 33(5):436-42. PubMed ID: 756675
    [No Abstract]   [Full Text] [Related]  

  • 8. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and biochemical considerations on depressive states occuring during parkinsonian syndrome treated by L-Dopa].
    Gisselmann A; Boudry C; Marin A; Ballivet J
    Encephale; 1976; 2(2):105-13. PubMed ID: 1278088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of Parkinson's syndrome using a new preparation from the series of tricyclic psychotropic drugs].
    Deze J; Völler GW
    Med Welt; 1975 Aug; 26(33-34):1457-62. PubMed ID: 1100988
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapy of Parkinson's syndrome with L-dopa only and in combination with a decarboxylase inhibitor. A comparison].
    Feise G; Paal G
    Nervenarzt; 1974 Mar; 45(3):126-32. PubMed ID: 4832035
    [No Abstract]   [Full Text] [Related]  

  • 12. [Variations of the therapeutic action (on-off phenomenon) in patients with Parkin].
    Carolei A; Casacchi M; Fazio C
    Clin Ter; 1977 Jan; 80(2):181-9. PubMed ID: 844268
    [No Abstract]   [Full Text] [Related]  

  • 13. [New directions in contemporary pharmacotherapy of parkinsonism (review)].
    Kurako IuL; Volianskiĭ VE
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1401-6. PubMed ID: 6150591
    [No Abstract]   [Full Text] [Related]  

  • 14. [Long-term levodopa syndrome. Report of a clinical case].
    Bossi L; Nobili M
    Arch Sci Med (Torino); 1978; 135(4):637-9. PubMed ID: 756726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 16. Trihexyphenidyl potentiation of L-DOPA: reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys.
    Domino EF; Ni L
    Exp Neurol; 1998 Aug; 152(2):238-42. PubMed ID: 9710523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug therapy of parkinsonism.
    Bianchine JR
    N Engl J Med; 1976 Oct; 295(15):814-8. PubMed ID: 958277
    [No Abstract]   [Full Text] [Related]  

  • 18. Postencephalitic stereotyped involuntary movements responsive to L-Dopa.
    Picard F; de Saint-Martin A; Salmon E; Hirsch E; Marescaux C
    Mov Disord; 1996 Sep; 11(5):567-70. PubMed ID: 8866499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
    Agid Y; Quinn N; Lhermitte F
    Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Letter: A severe case of postural hypotension. Paradoxical treatment by L-dopa combined with an inhibitor of extracerebral dopa-decarboxylase].
    Boismare F; Boquet J
    Nouv Presse Med; 1975 Feb; 4(8):589. PubMed ID: 1129119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.